mAbxience and Sandoz sign collaboration agreement for biosimilars access
mAbxience and Sandoz announced a licensing, development, and manufacturing collaboration agreement to advance biosimilar access worldwide.
Story updates
10:30:20 AM UTC
SquawkNews
mAbxience and Sandoz signed a licensing, development, manufacturing and commercialization deal for an emicizumab biosimilar. mAbxience develops and manufactures; Sandoz has exclusive global rights excluding Argentina, Uruguay and Paraguay. The reference market is ~$5.7B.Material DetailsContext by A…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.